Investors - Press Releases
|View printer-friendly version|
TRHC’s DoseMeRx® Partners with Physiomics to Provide Precision Dosing for Oncology Medications
Cancer remains one of the leading causes of death in developed countries and one of the most significant areas of spend for health systems. There are many effective cancer drugs; but, it is well established that, given the same dose, variations between individuals mean that different amounts of drug reach their tumours.
Using measurements of the amount of drug in a patient’s blood to guide what dose they should receive has been shown to improve efficacy and reduce side effects. The tests, however, are difficult to obtain in oncology because they are expensive and not standardized. Physiomics’ personalized dosing models currently rely only on inexpensive, standard blood tests that could help doctors and pharmacists in making decisions about the dose of cancer drugs for individual patients. TRHC’s DoseMeRx enables healthcare providers to optimize dosing and streamline operations, reduce adverse drug events, and decrease costs. The unique DoseMeRx platform incorporates Bayesian science to guide the safe and effective dosing of 42 different drugs.
Physiomics Chief Executive Officer,
TRHC Chief Scientific Officer
DoseMeRx® is a
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the
TRHC Media Contact
T: (215) 870-0829
TRHC Investor Contact
T: (866) 648-2767
+44 (0)1865 784 980
Source: Tabula Rasa HealthCare, Inc.